FDA panel votes against approving higher dose of Lilly-Incyte arthritis drug

(Reuters) - A U.S. FDA advisory committee voted 10-to-5 on Monday against approving a higher dose of a rheumatoid arthritis drug developed by Eli Lilly & Co and Incyte Corp, but recommended that it be approved in a lower dose.